Fuzuloparib Alone or With Apatinib Bests Chemo in BRCA-Mutat

Fuzuloparib, with or without apatinib, improved PFS over chemotherapy in patients with previously treated, HER2-negative, BRCA-mutated breast cancer.

Related Keywords

Beijing , China , Peking , United States , Huiping Li , University Cancer Hospital , Peking University Cancer Hospital ,